In a NASH mouse model, cardiolipin synthase 1 (CLS-1) inhibits the synthesis of cardiolipin, thereby suppressing the activation of the NLRP3 inflammasome and relieving NASH (Liu et al., 2019). Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.